Dyslipidemia and fasting glucose impairment among HIV patients three years after the first antiretroviral regimen in a Brazilian AIDS outpatient clinic

Brazilian Journal of Infectious Diseases

Volumn 17, Issue 4, 2013, Pages 438-443

  Pinto Neto, Lauro Ferreira da Silva ^a,b   Das Neves, Mariza Barros ^a   Ribeiro Rodrigues, Rodrigo ^b   Page, Kimberly ^c   Miranda, Angelica Espinosa ^b  

^a Escola Superior de Ciencias da Santa Casa de Misericordia de Vitoria   (Brazil)

^b FEDERAL UNIVERSITY OF ESPÍRITO SANTO   (Brazil)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; ART; Co morbidity; Dyslipidemia; Fasting glucose

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; FOSAMPRENAVIR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL THERAPY; ARTICLE; BRAZIL; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG USE; DYSLIPIDEMIA; FEMALE; FRAMINGHAM RISK SCORE; GLUCOSE BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTPATIENT DEPARTMENT; RETROSPECTIVE STUDY; TRIACYLGLYCEROL BLOOD LEVEL;

AIDS; ART; CO-MORBIDITY; DYSLIPIDEMIA; FASTING GLUCOSE;

ADULT; AMBULATORY CARE FACILITIES; ANTI-HIV AGENTS; BLOOD GLUCOSE; BRAZIL; COHORT STUDIES; DYSLIPIDEMIAS; FASTING; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84880942291     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/j.bjid.2012.12.006     Document Type: Article

References (31)

1. Marins J.R., Jamal L.F., Chen S.Y., Barros M.B., Hudes E.S., Barbosa A.A., et al. Dramatic improvement in survival among adult BrazilianAIDS patients. AIDS 2003, 17:1675-1682.
2. El-Sadr W.M., Mullin C.M., Carr A., Gibert C., Rappoport C., Visnegarwala F., et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naïve cohort. HIV Med 2006, 6:114-121.
3. Riddler S.A., Smit E., Cole S.R., et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003, 289:2978-2982.
4. Grunfeld C., Pang M., Doerrler W., Shigenaga J.K., Jensen P., Feingold K.R. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992, 74:1045-1052.
5. Brown T.T., Cole S.R., Li X., et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005, 165:1179-1184.
6. Palacios R., Merchante N., Macias J., et al. Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy. Antivir Ther 2006, 11:529-535.
7. Tien P.C. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007, 21:1739-1746.
8. Currier J.S., Lundgren J.D., Carr A., et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation 2008, 118:e29-e35.
9. Silva E.F., Bassichetto K.C., Lewi D.S. Perfil lipídico, fatores de risco cardiovascular e síndrome metabólica em um grupo de pacientes com AIDS. Arq Bras Cardiol 2009, 93:113-118.
10. Mamary E.M., Bahrs D., Martinez S. Cigarette smoking and the desire to quit among individuals living with HIV. AIDS Patient Care STDS 2002, 16:39-42.
11. Brasil.Ministério da Saúde. Departamento de DST AeHVSMdS Recomendações para terapia antiretroviral am adultos infectados pelo HIV-1 2008, 64.
12. NCEP Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel, III). JAMA 2001, 285:2486-2497.
13. Caramelli B., de Bernoche C.Y., Sartori A.M., et al. Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate. Braz J Infect Dis 2001, 5:332-338.
14. de Araujo P.S., de Alencar Ximenes R.A., Lopes C.F., Duarte J.Y., da Silva M.M., Carneiro E.M. Antiretroviral treatment for HIV infection/AIDS and the risk of developing hyperglycemia and hyperlipidemia. Rev Inst Med Trop Sao Paulo 2007, 49:73-78.
15. Turchi M.D. Dyslipidemia in AIDS patients on highly active antiretroviral therapy. Braz J Infect Dis 2011, 15:151-155.
16. Cardiologia DdAdSBd. IV Diretriz Brasileira sobre dislipidemias e prevenção de, aterosclerose. Arq Bras Cardiol 2007, 88:1-19.
17. Dubé M.P., Cadden J.J. Lipid metabolism in treated HIV infection. Best Pract Res Clin Endocrinol Metab 2011, 25:429-442.
18. Rose H., Hoy J., Woolley I., et al. HIV infection and high density lipoprotein metabolism. Atherosclerosis 2008, 199:79-86.
19. Boekholdt S.M., Kuivenhoven J.A., Wareham N.J., et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation 2004, 110:1418-1423.
20. Ceccato M.G., Bonolo P.F., Souza Neto A.I., Araújo F.S., Freitas M.I. Antriretroviral therapy-associated dyslipidemai in patients from a reference center in Brazil. Braz J Med Biol Res 2011, 44:1177-1183.
21. Hill A., Sawyer W., Gazzard B. Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clin Trials 2009, 10:1-12.
22. Feeney E.R. HIV and HAART-associated dyslipidemia. Open Cardiovasc Med J 2011, 5:49-63.
23. Lee G.A., Seneviratne T., Noor M.A., et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. AIDS 2004, 18:641-649.
24. Brown T.T. The effects of HIV-1 infection on endocrine organs. Best Pract Res Clin Endocrinol Metab 2011, 25:403-413.
25. Blanco F., San Román J., Vispo E., López M., Salto A., Abad V. Management of metabolic complications and cardiovascular risk in hIV-infected, patients. AIDS Rev 2010, 12:231-241.
26. Rudich A., Ben-Romano R., Etzion S., Bashan N. Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors. Acta Physiol Scand 2005, 183:75-88.
27. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3:e442.
28. Grinspoon S.K., Grunfeld C., Kotler D.P., et al. State of the science conference: initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 2008, 118:198-210.
29. Aslangul E., Assoumou L., Bittar R., et al. Rosuvastatin versus pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS 2010, 24:77-83.
30. Pereira A.C., Mota G.F.A., Cunha R.S., Herkenhoff F.L., Mill J.G., Krieger J.E. Angiotensinogen 235T allele "dosage" is associated with blood pressure phenotypes. Hypertension 2003, 41:25-30.
31. Silva E.F.R., Bassichetto K.C., e Lewi D.S. Perfil lipídico, fatores de risco cardiovascular e syndrome metabólica em um grupo de pacientes com AIDS. Arq Bras Cardiol 2009, 93:113-118.